| scholarly article | Q13442814 |
| P50 | author | P. Andrew Futreal | Q63232438 |
| Andrew Berchuck | Q114258102 | ||
| P2093 | author name string | Lancaster JM | |
| Marks JR | |||
| Frank TS | |||
| Miron A | |||
| Carney ME | |||
| Deffenbaugh AM | |||
| Fraser EG | |||
| Heron KA | |||
| Vinson VL | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 2433-2437 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Frequency of germline and somatic BRCA1 mutations in ovarian cancer | |
| P478 | volume | 4 |
| Q34939445 | A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells |
| Q33992208 | Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium |
| Q30276986 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes |
| Q34155131 | Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer |
| Q37605747 | BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different |
| Q37513137 | BRCA and Early Events in the Development of Serous Ovarian Cancer. |
| Q34032766 | BRCA-associated ovarian cancer: from molecular genetics to risk management |
| Q37277941 | BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells |
| Q94305238 | BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells |
| Q42061759 | BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer |
| Q36206491 | BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9 |
| Q33930051 | BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation |
| Q37248365 | Breast cancer epigenetics: normal human mammary epithelial cells as a model system |
| Q90452178 | Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? |
| Q35447780 | Classification of BRCA1 missense variants of unknown clinical significance |
| Q89529848 | Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma |
| Q28307436 | Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status |
| Q92638703 | Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations |
| Q33521701 | Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas |
| Q35881326 | Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis |
| Q37140001 | Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. |
| Q87446314 | Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer |
| Q47115415 | Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer. |
| Q36903256 | Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases |
| Q61442941 | Differentiating between cancer and normal tissue samples using multi-hit combinations of genetic mutations |
| Q64123086 | Estimating the number of genetic mutations (hits) required for carcinogenesis based on the distribution of somatic mutations |
| Q27694529 | Fine tuning chemotherapy to match BRCA1 status |
| Q92354777 | Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome |
| Q36108520 | Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic |
| Q55230708 | Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. |
| Q36534730 | Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer. |
| Q50980879 | Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. |
| Q97524475 | IQGAP1 control of centrosome function defines distinct variants of triple negative breast cancer |
| Q45870377 | Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms |
| Q35828679 | Improved survival in BRCA2 carriers with ovarian cancer |
| Q26782613 | Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential |
| Q36574427 | Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients |
| Q84817507 | Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers |
| Q35731663 | Loss of heterozygosity: what is it good for? |
| Q34992260 | Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas |
| Q86903646 | Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites |
| Q35546258 | Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing |
| Q37595954 | Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas |
| Q26747279 | Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention |
| Q48211870 | Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations |
| Q21129302 | The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies |
| Q37453854 | The contribution of BRCA1 and BRCA2 to ovarian cancer |
| Q42368096 | The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation |
| Q24791520 | The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer |
| Q37849207 | Viral and bacterial aetiologies of epithelial ovarian cancer |
Search more.